Erenumab 70 mg, 140 mg Suppliers & Bulk Manufacturers

Available Forms: Prefilled autoinjector

Available Strengths: 70 mg, 140 mg

Reference Brands: Aimovig (USA/EU)

Category: Neurology

Erenumab is a monoclonal antibody used for the prevention of migraines in adults. It works by blocking the CGRP (Calcitonin Gene-Related Peptide) receptor, which plays a key role in migraine attacks. Administered as a subcutaneous injection once monthly, it is available in 70 mg and 140 mg strengths via prefilled pen or syringe. Erenumab helps reduce the frequency of migraine days and is generally well-tolerated.

Product Description:

Erenumab is a fully human monoclonal antibody against the CGRP receptor itself, which sets it apart from fremanezumab and galcanezumab, which bind the CGRP ligand. Calcitonin gene-related peptide is released from trigeminal afferents during migraine and drives vasodilation and neurogenic inflammation; blocking the receptor was the first migraine prevention strategy designed specifically around migraine pathophysiology rather than borrowed from cardiology or epilepsy.

It is injected subcutaneously once a month for prevention of episodic and chronic migraine in adults, and is typically considered after two or more conventional preventives have failed or were not tolerated. Response is assessed after about three months. Tolerability is generally good; post-marketing experience added warnings for constipation, sometimes severe, and for new or worsened hypertension, both plausibly linked to CGRP's role outside the brain. Injection site reactions are common.

Sourcing notes. Originator biologic, on patent; no biosimilar is available. Supplied as a prefilled autoinjector that needs refrigeration, with limited tolerance for time at room temperature, so cold-chain integrity through distribution is part of any supply arrangement. Reimbursement bodies typically restrict use to patients failing prior preventives, which shapes volume. Treat enquiries as authorised-distributor supply.